Rezolute, Inc.
RZLT
NASDAQ·Healthcare·Biotechnology·Mkt cap $441.0M
$4.58
▲ +0.88%
P/E
-4.92
Mkt Cap
$441.0M
52-Wk Range
$1.07–$11.46
52-Week Range
$1.07 - $11.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 42.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage in monoclonal antibody therapy for congenital hyperinsulinism
- Focused pipeline targeting ultra-rare pediatric and metabolic disorders with limited competition
- Advanced understanding of glucose metabolism and endocrine regulation mechanisms
- Orphan drug designation potential enabling accelerated development pathways and market exclusivity
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Phase 2b clinical trial progression for RZ358 with potential for breakthrough therapy designation
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+12.3% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RZLT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 16, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$0.22.
Reported EPS · last 4Q
Q2 25
-$0.22
Q1 25
-$0.18
Q4 25
-$0.26
Q3 25
-$0.27
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Jul 30, 2026
vs Industry
How RZLT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related